These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 12880486)
1. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Ebadi M; Sharma SK Antioxid Redox Signal; 2003 Jun; 5(3):319-35. PubMed ID: 12880486 [TBL] [Abstract][Full Text] [Related]
3. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024 [TBL] [Abstract][Full Text] [Related]
4. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201 [TBL] [Abstract][Full Text] [Related]
5. Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Ebadi M; Sharma SK; Ghafourifar P; Brown-Borg H; El Refaey H Methods Enzymol; 2005; 396():276-98. PubMed ID: 16291239 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147 [TBL] [Abstract][Full Text] [Related]
7. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study. Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625 [TBL] [Abstract][Full Text] [Related]
8. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953 [TBL] [Abstract][Full Text] [Related]
9. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. Tripathy D; Chakraborty J; Mohanakumar KP Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946 [TBL] [Abstract][Full Text] [Related]
10. Mitochondrial impairment and melatonin protection in parkinsonian mice do not depend of inducible or neuronal nitric oxide synthases. López A; Ortiz F; Doerrier C; Venegas C; Fernández-Ortiz M; Aranda P; Díaz-Casado ME; Fernández-Gil B; Barriocanal-Casado E; Escames G; López LC; Acuña-Castroviejo D PLoS One; 2017; 12(8):e0183090. PubMed ID: 28800639 [TBL] [Abstract][Full Text] [Related]
12. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Zuo L; Motherwell MS Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870 [TBL] [Abstract][Full Text] [Related]
13. Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Itzhak Y; Martin JL; Ali SF Synapse; 1999 Dec; 34(4):305-12. PubMed ID: 10529724 [TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice. Yokoyama H; Yano R; Aoki E; Kato H; Araki T Metab Brain Dis; 2008 Sep; 23(3):335-49. PubMed ID: 18648914 [TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
16. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change. Shin EJ; Nam Y; Lee JW; Nguyen PT; Yoo JE; Tran TV; Jeong JH; Jang CG; Oh YJ; Youdim MBH; Lee PH; Nabeshima T; Kim HC Mol Neurobiol; 2016 Nov; 53(9):6251-6269. PubMed ID: 26563498 [TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and the pathogenesis of Parkinson's disease. Jenner P; Olanow CW Neurology; 1996 Dec; 47(6 Suppl 3):S161-70. PubMed ID: 8959985 [TBL] [Abstract][Full Text] [Related]
18. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274 [TBL] [Abstract][Full Text] [Related]